1178 related articles for article (PubMed ID: 30481203)
1. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis.
Korfei M; Skwarna S; Henneke I; MacKenzie B; Klymenko O; Saito S; Ruppert C; von der Beck D; Mahavadi P; Klepetko W; Bellusci S; Crestani B; Pullamsetti SS; Fink L; Seeger W; Krämer OH; Guenther A
Thorax; 2015 Nov; 70(11):1022-32. PubMed ID: 26359372
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
[TBL] [Abstract][Full Text] [Related]
5. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors.
Didiasova M; Singh R; Wilhelm J; Kwapiszewska G; Wujak L; Zakrzewicz D; Schaefer L; Markart P; Seeger W; Lauth M; Wygrecka M
FASEB J; 2017 May; 31(5):1916-1928. PubMed ID: 28148565
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.
Conforti F; Davies ER; Calderwood CJ; Thatcher TH; Jones MG; Smart DE; Mahajan S; Alzetani A; Havelock T; Maher TM; Molyneaux PL; Thorley AJ; Tetley TD; Warner JA; Packham G; Ganesan A; Skipp PJ; Marshall BJ; Richeldi L; Sime PJ; O'Reilly KMA; Davies DE
Oncotarget; 2017 Jul; 8(30):48737-48754. PubMed ID: 28467787
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
[TBL] [Abstract][Full Text] [Related]
9. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
11. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation.
Vu TN; Chen X; Foda HD; Smaldone GC; Hasaneen NA
Respir Res; 2019 Sep; 20(1):206. PubMed ID: 31511015
[TBL] [Abstract][Full Text] [Related]
12. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
Korfei M; Mahavadi P; Guenther A
Cells; 2022 May; 11(10):. PubMed ID: 35626663
[TBL] [Abstract][Full Text] [Related]
13. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
15. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.
Ghebremariam YT; Cooke JP; Gerhart W; Griego C; Brower JB; Doyle-Eisele M; Moeller BC; Zhou Q; Ho L; de Andrade J; Raghu G; Peterson L; Rivera A; Rosen GD
J Transl Med; 2015 Aug; 13():249. PubMed ID: 26231702
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice.
Sanders YY; Hagood JS; Liu H; Zhang W; Ambalavanan N; Thannickal VJ
Eur Respir J; 2014 May; 43(5):1448-58. PubMed ID: 24603818
[TBL] [Abstract][Full Text] [Related]
17. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.
Yu W; Guo F; Song X
Pharm Biol; 2017 Dec; 55(1):450-455. PubMed ID: 27937011
[TBL] [Abstract][Full Text] [Related]
18. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis.
Di Fazio P; Schneider-Stock R; Neureiter D; Okamoto K; Wissniowski T; Gahr S; Quint K; Meissnitzer M; Alinger B; Montalbano R; Sass G; Hohenstein B; Hahn EG; Ocker M
Cell Oncol; 2010 Jan; 32(4):285-300. PubMed ID: 20208142
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone in idiopathic pulmonary fibrosis.
Maher TM
Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
[TBL] [Abstract][Full Text] [Related]
20. Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo.
Ma Z; Zhao C; Chen Q; Yu C; Zhang H; Zhang Z; Huang W; Shen Z
Pulm Pharmacol Ther; 2018 Dec; 53():100-106. PubMed ID: 30394340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]